• Product nameAnti-CBFb antibody
    See all CBFb primary antibodies
  • Description
    Rabbit polyclonal to CBFb
  • SpecificityThis antibody detects CBFb.
  • Tested applicationsSuitable for: ICC/IF, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human, Zebrafish
    Predicted to work with: Chicken, Xenopus laevis
  • Immunogen

    Synthetic peptide:


    , corresponding to amino acids 1-20 of Human CBFb.

  • Positive control
    • HeLa whole cell lysates.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: 0.05% Sodium Azide
    Constituents: PBS, 1mg/ml BSA
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab33516 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/500. PubMed: 24648201
WB 1/500. Detects a band of approximately 22 kDa (predicted molecular weight: 22 kDa).


  • FunctionCBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. CBFB enhances DNA binding by RUNX1.
  • Involvement in diseaseNote=A chromosomal aberration involving CBFB is associated with acute myeloid leukemia of M4EO subtype. Pericentric inversion inv(16)(p13;q22). The inversion produces a fusion protein that consists of the 165 N-terminal residues of CBF-beta (PEPB2) with the tail region of MYH11.
  • Sequence similaritiesBelongs to the CBF-beta family.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CBF b antibody
    • CBF beta antibody
    • CBF-beta antibody
    • CBFB antibody
    • CBFbeta antibody
    • Core binding factor beta subunit antibody
    • core binding factor subunit beta antibody
    • Core-binding factor subunit beta antibody
    • PEA 2 antibody
    • PEA2 antibody
    • PEA2 beta antibody
    • PEA2-beta antibody
    • PEA2beta antibody
    • PEBB_HUMAN antibody
    • PEBP 2B antibody
    • PEBP2 beta antibody
    • PEBP2-beta antibody
    • PEBP2B antibody
    • PEBP2beta antibody
    • Polyomavirus enhancer binding protein 2 beta subunit antibody
    • Polyomavirus enhancer-binding protein 2 beta subunit antibody
    • SL3 3 enhancer factor 1 beta subunit antibody
    • SL3 3 enhancer factor 1 subunit beta antibody
    • SL3-3 enhancer factor 1 subunit beta antibody
    • SL3/AKV core binding factor beta subunit antibody
    • SL3/AKV core-binding factor beta subunit antibody
    see all

References for Anti-CBFb antibody (ab33516)

This product has been referenced in:
  • Cieslak A  et al. RUNX1-dependent RAG1 deposition instigates human TCR-d locus rearrangement. J Exp Med 211:1821-32 (2014). WB, IP ; Human . Read more (PubMed: 25135298) »
  • Lopez-Camacho C  et al. Core binding factor ß (CBFß) is retained in the midbody during cytokinesis. J Cell Physiol 229:1466-74 (2014). WB, ICC/IF ; Human . Read more (PubMed: 24648201) »

See all 7 Publications for this product

Product Wall

Application Western blot
Sample Mouse Cell lysate - whole cell (Mouse Embryonic stem cells Strain 129)
Loading amount 35 µg
Specification Mouse Embryonic stem cells Strain 129
Gel Running Conditions Reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C

Abcam user community

Verified customer

Submitted Oct 04 2010

Application Western blot
Sample Rat Cell lysate - whole cell (UMR-106 OSTEOSARCOMA)
Loading amount 50 µg
Specification UMR-106 OSTEOSARCOMA
Gel Running Conditions Reduced Denaturing (10% PAGE SDS)
Blocking step Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C

Mr. Cesar Camacho

Verified customer

Submitted May 06 2008